Corcept Therapeutics Inc. Stock
Corcept Therapeutics Inc. gained 0.980% compared to yesterday.
Corcept Therapeutics Inc. is currently one of the favorites of our community with 17 Buy predictions and no Sell predictions.
As a result the target price of 125 € shows a positive potential of 30.48% compared to the current price of 95.8 € for Corcept Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Corcept Therapeutics Inc. stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Revenue growth" there were negative voices in the community.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | 0.980% | -3.486% | 16.460% | 56.230% | 40.099% | 237.324% | 426.374% |
| Pacira Pharmaceuticals | -1.850% | -9.402% | -4.505% | 12.766% | -1.852% | -39.429% | -58.431% |
| Supernus Pharmaceuticals | -1.060% | -5.076% | -9.223% | 16.875% | -13.023% | 30.769% | 66.964% |
| Collegium Pharmaceutical Inc | 0.000% | -1.282% | -5.521% | 21.260% | -25.604% | 55.556% | 79.070% |
Comments
Corcept Therapeutics (CORT) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $165.00 price target on the stock, up from $88.00.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) had its price target raised by HC Wainwright from $95.00 to $165.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (CORT) was upgraded by Truist Financial Corporation to "strong-buy".
Show more
Ratings data for CORT provided by MarketBeat
News
Corcept Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Corcept Therapeutics Incorporated? Here are five stocks we like better.
- Second-quarter revenue rose 32% to $256.1 million, driven by growth in the Cushing’s syndrome
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know
Chief Financial Officer Mokari Atabak reported the sale of 40,000 shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) on July 15, 2026, according to an SEC Form 4 filing.
Transaction value
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound
James N. Wilson, a director at Corcept Therapeutics Incorporated (NASDAQ:CORT), sold 10,000 shares of the company on July 15, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC